Every 424B that Lexaria Bioscience Corp. (LEXX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow LEXX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LEXX filings page.
Lexaria Bioscience Corp. (LEXX) registers up to 923,827 common shares for resale by selling stockholders, all issuable upon exercise of Series A, Series B and placement-agent warrants. Lexaria receives no proceeds from stockholder resales; cash exercise of the warrants would provide an aggregate $11,760,182. Lexaria intends, if it receives proceeds, to use them for future research and development, working capital and general corporate purposes. The warrants may expire unexercised.
The Series A and Series B warrants each cover 453,969 shares and have a $12.67 exercise price. Both are immediately exercisable; Series A has a five-year term and Series B an 18-month term, each from the Effective Date defined in the Inducement Letters. Placement-agent warrants cover 15,889 shares, are immediately exercisable and have a $16.15 exercise price and a five-year term. Common shares outstanding were 2,106,528 as of October 1, 2026. The prospectus notes that the auditor’s report on the incorporated 2025 financial statements contains an explanatory paragraph regarding Lexaria’s ability to continue as a going concern.
Lexaria Bioscience Corp. is registering up to 2,754,756 shares of common stock for resale by existing investors. These shares are issuable upon the exercise of outstanding warrants from a December 2025 private placement and related placement agent compensation. The company will not receive any money from stockholders’ resale of these shares.
If the warrants are exercised for cash, Lexaria would receive approximately $3.3 million in gross proceeds, which it plans to use for research and development, working capital and general corporate purposes. The company had 24,887,446 shares outstanding as of December 26, 2025, and its stock trades on the Nasdaq Capital Market under the symbol “LEXX”, with a last reported price of $0.809 per share on January 13, 2026.
Lexaria Bioscience Corp. is offering 2,661,600 shares of common stock at $1.315 per share in a primary registered direct sale to institutional investors. Gross proceeds are expected to be $3,500,004.00, with net proceeds of about $3.0 million after placement fees and expenses, which the company plans to use to advance research and development, fund working capital and for other general corporate purposes.
Alongside the stock sale, Lexaria is issuing in a separate private placement warrants to purchase up to 2,661,600 additional shares at an exercise price of $1.19 per share. If all of these private placement warrants are exercised for cash, the company would receive roughly $3.1 million in additional net proceeds.
Shares outstanding were 22,225,846 as of December 14, 2025 and are expected to become 24,887,446 after this offering, excluding any warrant or option exercises. Based on a pro forma as adjusted net tangible book value of $0.35 per share as of August 31, 2025, investors buying in this offering face immediate dilution of $0.97 per share, and the company highlights risks related to stock price volatility, Nasdaq listing compliance and potential future dilution.